Alira Health’s Transformation Talks: Real-World Evidence Strategy Playbook

Multimedia
Published on:
April 15, 2022

Medical and healthcare data have been gathered through various channels over the last twenty years, and with recent innovations, it offers new opportunities, becoming a crucial factor in market access strategies and clinical research. In this episode of Alira Health‘s Transformation Talks, our host Kenny Carberry, Director of Clinical Development at Alira Health, and Romain Finas, Vice President of Real-World Evidence at Alira Health, will discuss how industry stakeholders can leverage RWD to be more efficient, cost-effective, and thus increase their benefits without compromising quality.

Listen to this podcast to discover how industry stakeholders may use RWD to be more efficient, cost-effective, and maximize their benefits without sacrificing data quality and why the role of patients as an essential aspect of data gathering and sourcing cannot be overlooked when considering RWE.

Meet our speakers:

Romain Finas – Vice President, Real-World Evidence, Alira Health

Romain Finas has been building the Real-World Evidence practice for AliraHealth since mid-2020. Before AliraHealth, Romain designed and implemented the“beyond the pill” strategy for MSD France. He started living labs to test and assess innovations based on real-time data routinely collected by practitioners, among other initiatives. Romain has 20 years of experience in consultancy, healthcare, and digital.

Meet our host:

Kenny Carberry – Director, Clinical Development, Alira Health

Kenny leads business development efforts and initiatives for early-stage healthcare companies. His background covers various indications across pharma, medical devices, and digital health. In addition to his expertise in business development, Kenny has several years of experience in clinical trial operations and management. He offers a unique perspective on the clinical development lifecycle, from generating a comprehensive strategy to executing a successful trial.

LISTEN TO THE “REAL-WORLD EVIDENCE STRATEGY PLAYBOOK” EPISODE NOW

Related news

Publications September 16, 2022
Considerations for Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials
The rise of technology in clinical research allows us to capture meaningful aspects of health in clinical study participants.
Biometrics Clinical eCOA
Publications September 7, 2022
The Promise and Reality of Decentralized and Hybrid Clinical Trials in Europe Today
To understand the challenges related to hybrid and decentralized trials and ways to overcome them, we spoke with Dr. Hervé Solatges, Product Management, Evidence, and Innovation (DCT(...)
Clinical Decentralized Clinical Trials Hybrid Clinical Trials
News September 5, 2022
Alira Health and Legit.Health Partner to Empower Patients in Dermatology Clinical Research
Alira Health digital health solutions combined with Legit.Health’s AI-driven image assessment tool offer a unique platform for dermatology DCT, RWE and DTx.
Decentralized Clinical Trials Dermatology DTx RWE
Publications September 5, 2022
Taking In-Licensed Biologics to Market: Challenges, Complexities, and Ways to Overcome Them
Taking a biologic through drug development to market is highly complex and filled with challenges. To understand these challenges, their implications and how to overcome them, we spoke(...)
Biologics Clinical Drug Development
News August 17, 2022
Alira Health Joins the IRB Barcelona to Advance the Development of Personalized Cancer Treatments
We are pleased to announce we are joining the Institute for Research in Biomedicine (IRB Barcelona) as part of the CGI-Clinics project.
Patient Centric Real-World Evidence RWE
Events August 10, 2022
DPHARM
We are pleased to announce that we will be sponsoring and attending DPHARM, a unique event focused on the latest innovations that modernize clinical trials.
Clinical Decentralized Clinical Trials DPHARM Patient Centric
Publications August 2, 2022
GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2
The last two years have brought forward tremendous advances in the development of prophylactic and therapeutic approaches for the treatment of SARS-CoV-2 infections.
Clinical CMC Vaccines
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.